Neuroglee Therapeutics, a Singapore-based healthtech startup building evidence-based, prescription digital therapeutics for neurodegenerative diseases, announced today that it has raised US$2.3 million in pre-seed funding.
The round was led by Eisai, a Japanese global pharmaceutical company. Kuldeep Singh Rajput, Founder & CEO of Biofourmis, also participated in the investment round.
As per a press note, proceeds will be used to advance product development for their lead product NG-001 – intended for the treatment and management of patients with early stages of Alzheimer’s Disease. Clinical trials are due to start in early 2021 and the startup plans to open its US operations in Boston in 2021.
Neuroglee designs and commercialises digital therapies to fill the unmet need for complementary therapies to manage neurodegenerative diseases that can run in parallel with pharmacotherapy or treatment through medication.
Combining closed-loop cognitive intervention strategies and novel biomarkers, Neuroglee claims its prescription software can be used independently and in conjunction with pharmacotherapy for better patient management, creating a more holistic approach to treatment for neurodegenerative diseases.
NG-001 is designed to manage patients with early-stage Alzheimer’s by delivering software-based cognitive intervention at home.
Leveraging on Artificial Intelligence, the software deploys engaging gamification techniques and cognitive tasks on a digital tablet. The solution constantly tracks a patient’s cognitive function using digital biomarkers and dynamically personalises tasks and intervention for the patient.
South Africa Today
Read more at VolaNews
